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Abstract
Background. Warfarin dose requirements are partly determined by common single nucleotide polymorphisms 
in VKORC1 and CYP2C9 genes.
Objectives. The aim of this study was to investigate how the presence of allelic variants in CYP2C9 affects the sta-
bility of anticoagulation in patients within the first 3 months following elective heart valve replacement.
Material and Methods. In a case-control study we compared 18 consecutive carriers of CYP2C9*2 and/or *3 and 
25 well-matched patients with the wild type CYP2C9*1/*1 genotype. The former group was randomly assigned to 
use coagulometers or monitor international normalized ratio (INR) in local outpatient clinics. Subjects receiving 
drugs potently interfering with warfarin were ineligible. Anticoagulation with the baseline warfarin regimens based 
on pharmacogenetic algorithm was assessed by time in the therapeutic INR range (TTR) within the first 3 months 
following implantation.
Results. Carriers of the CYP2C9*2  and/or *3  genotypes were characterized by lower estimated warfarin dose 
(median, 21 [interquartile range, 21–35] vs. 35 [28–42] mg/week, p  = 0.02) and actual (27.8  ± 13.2  vs. 46.3   
± 13.9 mg/week, p < 0.001), together with lower TTR values (56 [38.6–74.9] vs. 75.4 [58.1–83.6] %, p = 0.03) and 
longer time above the therapeutic range (13.8  [4.9–34.5] vs. 4.5  [0–15.3] %, p  = 0.047) than patients with the 
CYP2C9*1/*1  genotype. There were no differences in the estimated and actual warfarin doses, TTR values and 
adverse events between the self-testing and standard-care subgroups.
Conclusions. The presence of CYP2C9*2 and/or *3 genotypes is associated with unstable warfarin treatment in 
patients after heart valve replacement, regardless of the type of INR testing (Adv Clin Exp Med 2015, 24, 4, 
607–614).
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its anticoagulant effect by inhibiting the recycling 
of oxidized vitamin K to the reduced form (KH2) 
by vitamin K  epoxide reductase complex sub-
unit 1 (VKORC1) in the liver. Vitamin KH2 serves 
as a  cofactor in carboxylation of glutamate resi-
dues (Gla) on the  N-terminal regions of vitamin 
 K-dependent blood coagulation factors (F), i.e. FII, 
FVII, FIX, and FX  [4]. Treatment with warfarin 
Despite increasing clinical use of direct throm-
bin and factor (F) Xa inhibitors, mainly in non-
valvular atrial fibrillation (AF), 4-hydroxycouma-
rin derivatives – vitamin K  antagonists (VKAs) 
– are used in the prevention of valve thrombo-
sis and arterial thromboembolism in patients 
with artificial heart valves [1–3]. The most com-
monly used VKA worldwide, warfarin, exhibits 
* This work was supported by a grant from the National Center of Science (N N403 152340 to A.U.).
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results in the hepatic production of partially car-
boxylated and decarboxylated proteins with re-
duced coagulant activity. 
However, VKA therapy is challenging because 
of its narrow therapeutic index combined with the 
wide inter-individual dosing variation. The effica-
cy and safety of warfarin treatment are highly de-
pendent on the time in which the international 
normalized ratio (INR) is in the therapeutic range 
(TTR) [5]. A  maintenance dose of VKA depends 
on several factors, predominantly diet and medica-
tions, or individual features such as age and body 
weight as well as genetics factors [6]. VKORC1 and 
cytochrome P450 (CYP) 2C9 genetic variants con-
tribute largely to inter-individual variations in war-
farin dose requirements affecting its pharmacody-
namics and pharmacokinetics, respectively [7, 8]. 
The CYP2C9 gene is located on chromosome 10q24 
and encodes the cytochrome P450 enzyme that me-
tabolizes the S-warfarin isoform, which is 2.7  to 
3.8 times more potent than the R enantiomer [6]. 
The major CYP2C9 polymorphisms, CYP2C9*2 
in exon 3  (p.Arg144Cys, c.430C > T, rs1799853) 
and CYP2C9*3 in exon 7  (p.Ile359Leu, c.1075A 
>  C, rs1057910) are associated with reduced en-
zyme activity [2, 6]. In vitro study has shown that 
intrinsic clearance of S-warfarin was 5.5-fold and 
27-fold lower when the reaction was catalyzed by 
enzymes encoded by CYP2C9*2 and CYP2C9*3 al-
lelic variants, respectively, compared with the wild 
type genotype CYP2C9*1/*1 [9]. Patients with the 
VKORC1 wild type and the CYP2C9*1/*2 geno-
types require approximately the same dose of war-
farin [10]. In the presence of any of the genotypes 
– CYP2C9*2/*2, CYP2C9*2/*3 or CYP2C9*1/*3 to-
gether with the VKORC1 wild type variant, a war-
farin dose is decreased approximately 1.7-fold 
compared to the CYP2C9*1/*1 variant. Subjects 
with the CYP2C9*3/*3 variant require approx-
imately from 3.5  to 10-fold lower dose of warfa-
rin to achieve therapeutic INR compared to the 
 CYP2C9*1/*1 variant [10].
The carriers of the CYP2C9*2 and/or 
 CYP2C9*3 allele, who represent 10% and 6% of 
the European population, respectively, have an 
increased risk of bleeding complications, espe-
cially at the beginning of anticoagulation therapy 
and need a longer time to stabilize the VKAs dose 
[2, 11, 12]. The risk of bleeding complications dur-
ing warfarin treatment has been increased by 90% 
for CYP2C9*2  and by 80% for CYP2C9*3  allele 
variants [2]. However, this data was derived mostly 
from studies performed in patients for whom the 
most frequent indication for warfarin treatment 
was AF (up to 60%), and then venous thrombo-
embolism (VTE) (up to 40%). Patients after heart 
valve replacement have constituted less than 10% 
of all participants in the large published studies re-
garding the role of genetic polymorphisms in the 
optimization of VKA therapy [13–15]. 
Patients following mitral or aortic valve im-
plantation have a  relatively high risk of bleeding 
complications and exhibit a slightly different pro-
file of bleeding and thromboembolic risk as com-
pared to those with AF. It has been reported that 
total bleeding incidence is higher in patients after 
mitral valve replacement (32.3%) than in those af-
ter aortic valve replacement (21.8%), whereas the 
incidence of clinically relevant moderate or severe 
bleeding is not significantly different among the 
groups during 13 months of follow-up [16]. Simi-
larly, Schapkaitz et al. have reported that there was 
no significant difference in overall bleeding inci-
dence between the mechanical valve replacement 
subgroups and the control group over a 4-month 
follow-up [17]. However, patients with double 
(aortic and mitral) valve replacements had a high-
er proportion of combined bleeding and thrombo-
embolic complications (30.61%) than patients with 
single aortic or mitral valve replacements (14.29% 
vs. 18.05%, respectively) and patients in the con-
trol group (12.87%) [17]. 
To the best of our knowledge, most of the stud-
ies concerning the genetic associations with quali-
ty of anticoagulation and adverse events have been 
performed on AF and VTE patients and the sub-
jects after heart valve replacement have not been 
analyzed separately. Therefore, we sought to eval-
uate the relationship between CYP2C9 polymor-
phisms and TTR in this subset of anticoagulated 
patients in whom INR was monitored using 2 dif-
ferent approaches, i.e. self-testing and standard 
care. 
Aim of the Study
The aim of study was to investigate how al-
lelic variants in CYP2C9 affect the stability of an-
ticoagulation with warfarin in patients within 
the first 3  months following elective heart valve 
replacement.
Material and Methods
Between March and October 2013, 18 consec-
utive carriers of CYP2C9 *2 and/or *3 and 25 pa-
tients with wild type CYP2C9 *1/*1 were enrolled. 
The inclusion criteria were: age of at least 18 years, 
elective aortic and/or mitral valve replacement and 
need to use warfarin for at least 3 months. The ex-
clusion criteria were: acute infective endocardi-
tis, renal failure (creatinine > 200 umol/L), acute 
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vascular incident within 3 months prior to enroll-
ment, psychiatric diseases, alcoholism, the use of 
thienopyridines, oral corticosteroids or immuno-
suppressive agents. Subjects receiving drugs in-
terfering with warfarin, including amiodarone, ri-
fampicin, carbamazepine, antifungal azole agents, 
ritonavir and barbiturates, were ineligible. 
Demographic and clinical characteristics of 
the patients were recorded prior to surgery. Arte-
rial hypertension was diagnosed based on blood 
pressure > 140/90 mm Hg or preadmission of an-
tihypertensive treatment. Smoking was defined as 
the daily use of 1 or more cigarettes. Patients re-
ceiving insulin or oral hypoglycemic drugs, or 
having at least 2  random fasting glucose levels 
of >  7  mmol/L  were classified as having diabe-
tes mellitus. The left ventricular ejection frac-
tion was measured by Doppler echocardiogra-
phy using the modified Bernoulli equation. All 
patients gave written informed consent and the 
study was approved by the University Bioethi-
cal Committee.
Carriers of mutations in CYP2C9 were ran-
domly assigned to 2 groups: (1) using coagulome-
ters at home to measure INR (Alere INRatio®2 PT/ 
/INR Monitoring Systems, ALERETM, San Diego, 
CA, USA) and (2) monitoring INR values in a stan-
dard manner at the primary care physician’s or local 
cardiologist’s discretion. The former group was in-
structed to use the point-of care INR devices weekly 
to self-test at home. The self-testing group received 
INR testing instruction, including data interpreta-
tion and coping with typical issues of the measure-
ments. Training was initiated as soon after valve re-
placement as the patient’s clinical state allowed and 
was completed before discharge. The first INR mea-
surement was performed by a physician and there-
after by the patients. If there were any doubts in the 
measurement procedure, the patient was excluded 
from the self-testing group. In some cases, the pa-
tient’s family member was also trained. When INR 
was out of the therapeutic range, the patient was re-
quired to consult with the physician. 
The latter group and patients with the wild 
type CYP2C9*1/*1 genotype measured INRs in lo-
cal outpatient clinics at least once every 3–4 weeks. 
The estimated warfarin dose was obtained from 
the online algorithm (http://www.warfarindosing.
org) for each patient within 72 h after the surgery. 
The first warfarin dose was administered after re-
moval of the epicardial electrode (5–10 days af-
ter surgery). Further doses of warfarin were modi-
fied based on the INR measurements. Within the 
first 2 weeks, measurements were performed every 
2–3 days and then every 7–9 days, until the main-
tenance dose was established. To reliably calculate 
TTR, we defined a  sufficient number of available 
INRs within the first 3 months since surgery study 
as 3.
The target INR range was 2.5–3.5  for mitral 
and 2.0–3.0  for aortic heart valve in accordance 
with the European Society of Cardiology (ESC) 
guidelines. The quality of warfarin dosing was as-
sessed by the percentage of TTR, as described by 
Rosendaal et al. [5]. The last INRs were determined 
at a follow-up outpatient visit in the hospital labo-
ratory after 3 months (90 ± 13 days) since surgery. 
At that visit we recorded adverse events, includ-
ing death, minor (nose bleeds, subconjunctival 
hemorrhage, bruises and skin hematomas) and se-
vere bleeds (hemorrhagic stroke, gastrointestinal 
bleeding) as well as thromboembolic events (valve 
thrombosis, transient ischemic attack, stroke, myo-
cardial infarction, venous thromboembolism or 
other thrombotic episode), that were documented 
in medical records and/or self-reported.
DNA was isolated from whole blood collect-
ed in EDTA using the QIAamp® DNA Blood 
Mini Kit (QIAGEN, Valencia, CA) and stored at 
–80°C until analysis according to the manufactur-
er’s  protocol. Genotyping of VKORC1 (c.-1639G 
> A; rs9923231), CYP2C9*2 (p.Arg144Cys, c.430C 
> T; rs1799853) and CYP2C9*3  (p.Ile359Leu, 
c.1075A > C; rs1057910) SNPs was determined by 
the allelic discrimination test using TaqMan Ge-
notyping assays and the ABI PRISM 7900HT Fast 
Real-Time PCR System (Life Technologies Co., 
Carlsbad, CA, USA; assays IDs: C_30403261_20, 
C_25625805_10 and C_27104892_10, respective-
ly). The genotype determination was confirmed by 
positive and negative controls.
Statistical Analysis
The normality of data distribution was test-
ed using the Shapiro-Wilk test. Data was shown as 
mean ± standard deviation or median (interquar-
tile range), as appropriate. Differences between 
2 independent groups were compared with a Stu-
dent’s t-test or Mann-Whitney U test. Differences 
between the estimated and actual warfarin doses 
were assessed by Wilcoxon test. Qualitative da-
ta was compared by the Fisher exact test. Distri-
bution of genotypes was evaluated by the χ2 test. 
A p-value < 0.05 was considered statistically signif-
icant. Analysis was performed with STATISTICA 
v. 9.0 (StatSoft Inc., Tulsa, Oklahoma, USA).
Results
Patient characteristics are presented in Ta-
ble 1. The prevalence of the CYP2C9 *2 and *3 al-
lele (for a  total of 43 patients) was: 0.17: CC-30 
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Table 1. Patient characteristics
 Non-carriers of 
CYP2C9*2/3 
(n = 25)








Age (year) 63.7 ± 9.5 65.2 ± 7.3 0.38 63.0 ± 2.4 66.9 ± 9.4 0.27
Male, n (%) 17 (68) 11 (61.1) 0.44  4 (50)  7 (70) 0.35




22 (88) 14 (77.8) 0.31  5 (62.5)  9 (90) 0.21
Hypercholesterolemia, 
n (%)
23 (92) 14 (77.8) 0.19  6 (75)  8 (80) 0.62
Diabetes, n (%)  7 (28)  3 (16.7) 0.31  1 (12.5)  2 (20) 0.59
CAD, n (%) 11 (44)  6 (33.3) 0.35  1 (12.5)  5 (50) 0.12
Atrial fibrillation, n (%)  9 (36)  7 (38.9) 0.55  3 (37.5)  4 (40) 0.65
LVEF (%) 55.0 (47.0–60.0) 59.5 (50.0–67.0) 0.30 52.0 (42.5–67.5) 62.0 (55.0–67.0) 0.45
Symptomatic HF, n (%)  0  2 (11.1) 0.17  1 (12.5)  1 (10) 0.71
Current smoking, n (%)  2 (8)  0 0.33  0  0 n.a.
Medications
Beta-blockers, n (%) 23 (92) 15 (83.3) 0.34 5 (62.5) 10 (100) 0.07
Aspirin, n (%) 11 (44) 11 (61.1) 0.21 5 (62.5)  6 (60) 0.65
VKA, n (%)  9 (36)  6 (33.3) 0.56 2 (25)  4 (40) 0.44
Statin, n (%) 20 (80) 12 (66.7) 0.26 6 (75)  6 (60) 0.44
ACEI, n (%) 15 (60) 10 (55.6) 0.51 5 (62.5)  5 (50) 0.48
Surgery and its complications
Aortic valve replacement, 
n (%)
20 (80) 14 (77.8) 0.58 5 (62.5) 9 (90) 0.21
Mitral valve replacement, 
n (%)
 3 (12)  2 (11.1) 0.66 1 (12.5) 1 (10) 0.71
Both valves replacement, 
n (%)
 2 (8)  2 (11.1) 0.56 2 (25) 0 0.18
Major thrombotic compli-
cations, n (%)
 1 (4)  1 (5.5) 0.67 0 1 (10) 0.56
Minor bleeding complica-
tions, n (%)
 5 (20)  4 (22.2) 0.58 2 (25) 2 (20) 0.62
Anticoagulant therapy
TTR (%) 75.4 (58.1–83.6) 56.0 (38.6–74.9) 0.03 42.5 (36.0–55.7) 62.4 (54.5–79.6) 0.08
Above TTR (%)  4.5 (0.0–15.3) 13.8 (4.9–34.5) 0.05 10.2 (2.5–32.6) 16.0 (8.1–34.5) 0.63
Below TTR (%) 16.7 (8.2–32.1)  6.7 (0.0–58.2) 0.56 45.1 (2.0–59.5)  1.2 (0.0–27.1) 0.25
Number of INR measure-
ments
 7.9 ± 2.5  9.0 ± 2.9 0.2 10.1 ± 3.2  8.1 ± 2.3 0.14
Warfarin estimated dose 
(mg/week)
35.0 (28.0–42.0) 21.0 (21.0–35.0) 0.02 21.0 (21.0–31.5) 21.0 (21.0–35.0) 0.69
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(69.8%), CT-11 (25.6%) and TT-2 (4.6%) and 0.07: 
AA-37 (86%), AC-6  (14%) and CC-0  (0%), re-
spectively. The distribution of CYP2C9 *2  and 
CYP2C9*3 genotypes was in accordance with the 
Hardy-Weinberg equilibrium (p  = 0.54 and 0.24, 
respectively).
The patients with CYP2C9 *2  and/or *3  al-
lele and the control subjects with the CYP2C9 
*1/*1 genotype did not differ with regard to de-
mographic data, clinical factors, the prevalence of 
VKORC1 -1639G > A polymorphism and number 
of INRs measurements (Table 1).
In the group with CYP2C9 *2  or *3  allele, 
there were 14 (77.8%) patients following aortic, 
2 (11.1%) following mitral and 2 (11.1%) with both 
aortic and mitral valve replacement. The CYP-
2C9*2 allelic variant was observed in 12 (66.7%) 
patients, while the CYP2C9*3  allelic variant was 
found in 5 (27.8%) patients. There was one (5.5%) 
patient with the both variants. The VKORC -1639G 
> A polymorphism, i.e. the GA or AA genotypes, 
was detected in 12 (66.7%) patients with the CYP-
2C9 *2 or *3 allele.
During the first 3  postoperative months, no 
death or hemorrhagic or ischemic strokes were 
noted in either group. Transient ischemic at-
tack occurred in 1  (4%) patient with the CYP-
2C9*1*1  variant and in 1  (5.5%) patient with 
a  CYP 2C9*1*3  mutation. Gastrointestinal bleed-
ing was observed in 2  (8%) patients without mu-
tation in the CYP2C9 gene. Subconjunctival 
hemorrhage was observed in 2 (11%) patients with 
CYP2C9*1*3  and CYP2C9*2*3  mutations. Nose-
bleed was recorded in 1  patient with the CYP-
2C9*2  variant. Bruises and skin hematomas were 
reported by one (5.6%) patient with the CYP-
2C9*2 mutation and in 3  (12%) patients with the 
CYP2C9*1*1 genotype. Taken together, there were 
no differences between groups in the incidence of 
thromboembolic and hemorrhagic complications. 
As expected, the carriers of CYP2C9*2 and/or 
*3 variants had 40% lower both estimated and ac-
tual warfarin doses than the patients with the wild 
type CYP2C9*1/*1  genotype. In contrast to the 
wild-type carriers, no differences between the esti-
mated and actual warfarin doses in patients having 
CYP2C9*2 and/or *3 variants were observed (Ta-
ble 1).
The carriers of mutations in CYP2C9 were 
characterized by lower TTR (56.0  [38.6–74.9] vs. 
75.4  [58.1–83.6] %, p  = 0.03) and spent a  lon-
ger time in which the INR was above the thera-
peutic range (13.8  [4.9–34.5] vs. 4.5  [0–15.3] %, 
p = 0.047) than the wild type patients. 
There were no significant differences between 
the self-testing (n  = 8, 44%) and standard-care 
(n  = 10, 56%) groups with regard to demograph-
ic and clinical characteristics (Table 1). There were 
also no differences in the frequency of the studied 
allelic variants. However, in the self-testing group, 
the CYP2C9*3 variant was less frequent than in the 
standard-care group (1 carrier, 12.5% vs. 4 carriers, 
 Non-carriers of 
CYP2C9*2/3 
(n = 25)








Warfarin actual mean 
dose (mg/week)
46.3 ± 13.9 27.8 ± 13.2 < 0.001 30.1 ± 16.3 27.1 ± 11 0.78
Differences between the 












CYP2C9*2, n (%) 0 12 (66.7) < 0.001 6 (75) 6 (60) 0.44
CYP2C9*3, n (%) 0  5 (27.8) 0.009 1 (12.5) 4 (40) 0.23
Both allelic variants of 
CYP2C9, n (%)
0  1 (5.5) 0.42 1 (12.5) 0 0.44
VKORC1 -1639G > A, 
n (%)
19 (76) 12 (66.7) 0.37 4 (50) 8 (80) 0.20
Data is given as mean ± SD, median (interquartile range) or number (percentage). ACEI – angiotensin-converting enzyme 
inhibitor; BMI –body mass index; CAD – coronary artery disease; CYP2C9 – cytochrome P450 2C9; HF – heart failure; 
LVEF – left ventricular ejection fraction; TTR – time within therapeutic range; VKA – Vitamin-K antagonist; VKORC1 –  
– vitamin K epoxide reductase complex subunit 1. 
* – association between the estimated and actual warfarin doses within a group.
Table 1. Patient characteristics (cn.)
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40%, respectively), with one patient (12.5%) with 
both mutated CYP2C9 allelic variants. No differenc-
es in the estimated and actual warfarin doses, TTR 
values and adverse events between the self-testing 
and standard-care subgroups were observed.
Discussion
The current study demonstrated that in pa-
tients following elective heart valve replacement 
the common allelic CYP2C9*2  and/or *3  variants 
are associated with lower warfarin dosing and low-
er TTR in comparison to the CYP2C9*1/*1 geno-
type evaluated within the first 3 months of antico-
agulation. This finding is consistent with previous 
reports published mainly for patients with AF 
and/or VTE [13–15, 18]. Importantly, our study 
shows a  similar impact of the two CYP2C9 muta-
tions on the quality of anticoagulation in heart valve 
recipients with several comorbidities, e.g. heart fail-
ure, which might be perceived as factors that con-
tribute to large variations in TTR and INR values. 
The TTR value of the most common patient 
group, i.e. subjects with the CYP2C9*1/*1  geno-
type, was 75.4% and was even higher or similar to 
those reported previously, mostly for AF patients 
[13, 19, 20]. This highlights the good quality of 
warfarin therapy in Polish patients after valve im-
plantation, which indicates a  large improvement 
in TTR values in everyday practice nowadays, al-
though compared to countries with the best quali-
ty of anticoagulation, e.g. Sweden, Poland, without 
anticoagulation clinics, still has an overall subopti-
mal quality of long-term VKA treatment.
In the current study, patients possessing mu-
tated allelic variants of the CYP2C9 gene had lower 
both estimated and actual warfarin doses than pa-
tients with the CYP2C9*1/*1 genotype. This is in line 
with the previous reports concerning Turkish and 
Lithuanian patients after heart valve replacement 
where carriers of CYP2C9*2 and/or CYP2C9*3 gen-
otypes required a  lower maintenance dose of war-
farin than patients with the CYP2C9*1/*1 wild-type 
genotype [21, 22]. Furthermore, in our study, no 
differences between the estimated and actual warfa-
rin doses and no significant bleeding complications 
in carriers of CYP2C9*2  and/or *3  were observed. 
On the contrary, in the CYP2C9*1*1 group, differ-
ences between the estimated and actual warfarin 
doses were observed. It may be speculated that in 
our study group the pharmacogenetics algorithm is 
less helpful for patients without mutations in CYP-
2C9 requiring the intermediate warfarin dosing, as 
has been found previously [23]. The Internation-
al Warfarin Pharmacogenetics Consortium has re-
ported that a pharmacogenetics algorithm was more 
accurate for patients requiring lower (≤ 21 mg per 
week) or higher doses (≥ 49 mg per week) of warfa-
rin than a clinical algorithm. For patients requiring 
≤ 21 mg per week, the pharmacogenetic algorithm 
has given 50% of patients a well-predicted dose of 
warfarin, while the clinical algorithm has given only 
33% [23]. In our study, we confirmed that the phar-
macogenetic algorithm may be a useful for the esti-
mation of appropriate anticoagulation with warfa-
rin in patients who require the lower warfarin doses. 
However, in this group of patients, the strong influ-
ence of CYP2C9 variants was demonstrated in a less 
stable anticoagulation reflected by shorter TTR and 
a longer period where the INR was above the thera-
peutic range. These results might suggest that care-
ful warfarin dosing and more frequent INR test-
ing in the group with CYP2C9*2 or *3 variants are 
necessary.
INR testing can be done in outpatient clinics or 
by patients themselves at home. Self-testing of INRs 
has become more and more popular in Europe. In 
the current study, no differences were found in TTR 
or adverse event occurrence between the self-testing 
and standard-care groups. Similarly, previous studies 
in a large cohort of patients mostly with AF and af-
ter mechanical heart valve implantation have shown 
no differences in frequency of the first stroke, major 
bleeding complications and death between the self-
testing and standard-care group [24]. However, bet-
ter TTR has been achieved in the self-testing group 
than the standard care group [19, 24]. We did not 
find these associations probably due to the limited 
size of our study group. Similarly, bleeding episodes 
were not associated with the presence of the mutat-
ed variants of CYP2C9, probably due to the small 
number of patients. However, in a recently report-
ed case-control study where patients after heart valve 
replacement constituted 20 and 10%, respective-
ly, the CYP2C9*2/*3 and VKORC1 variants showed 
only a non-significant trend toward increased major 
bleeding risk in the initial 6 months of warfarin use 
[25]. It might be concluded that self-testing in every-
day practice among mostly elderly patients is not su-
perior to the standard care if the INR measurements 
are performed regularly, the patients are instructed 
on the risk and benefits from the therapy and modi-
fication of warfarin dosage is promptly recommend-
ed. Self-testing should be limited to anticoagulated 
patients who have objective obstacles to measure 
INR in outpatient clinics, e.g. logistical problems to 
reach them at least every 3–4 weeks.
Limitations
First, the major limitation of the current study 
is the small size of the patient groups. However, the 
impact of the 3 genetic polymorphisms evaluated 
CYP2C9 Polymorphism and Anticoagulation 613
in the context of TTR was potent enough to be ob-
served. Second, follow up in our study was restrict-
ed to the first three postoperative months, and 
a  longer follow-up might provide additional da-
ta, including the postoperative long-term clinical 
outcome, especially bleedings associated with the 
various genotypes. Finally, the current observa-
tions cannot possibly be extrapolated on patients 
receiving other VKAs, in particular acenocouma-
rol, which is still the most commonly used VKA 
in Poland. There are some differences in the role 
of the polymorphisms studied in the stability of 
anticoagulation with acenocoumarol versus war-
farin [9].
The authors concluded that CYP2C9*2 and/or 
*3 variants increase the risk of unstable anticoag-
ulation with warfarin in patients within the first 
3 months following heart valve replacement. INR- 
-self testing does not deteriorate the anticoagulation 
control in patients with CYP2C9 variants in com-
parison to patients who monitor the INR in local 
outpatient clinics. Genotyping of CYP2C9*2 and/or 
*3 variants might improve outcome in patients af-
ter heart valve replacement.
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